Programs

To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

Sports and Health Research Program: Pilot Projects on Sports-Related Brain and Spinal Cord Injury Research

Pilot Projects on Sports-Related Brain and Spinal Cord Injury Research is a component of the Sports and Health Research Program (SHRP) that funds pilot projects for research on sports-related traumatic brain injury and spinal cord injury research.

Accelerating Medicines Partnership: Type 2 Diabetes Project

https://www.nature.com/articles/s41586-019-1231-2The Accelerating Medicines Partnership Type 2 Diabetes Project (AMP T2D), is a multi-sector, pre-competitive partnership among government, industry, and nonprofit organizations, the goal of which is to harness collective capabilities, scale and resources toward improving current efforts to develop new therapies for complex, heterogeneous diseases.

Sports and Health Research Program: Chronic Traumatic Encephalopathy and Delayed Effects of Traumatic Brain Injury

Chronic Traumatic Encephalopathy and Delayed Effects of Traumatic Brain Injury is a component of the Sports and Health Research Program. It seeks to more fully characterize the neuropathology associated with chronic traumatic encephalopathy (CTE) and delayed effects of traumatic brain injury through systematic, rigorous and collaborative studies of post-mortem biospecimens.

Lung-MAP: Master Protocol for Treatment of Non-Small Cell Lung Cancer

Lung-MAP is an umbrella protocol which contains a screening component and multiple independently conducted and analyzed treatment sub-studies. The overarching hypothesis is that the umbrella master protocol will establish genomic screening for a large population of previously treated Non-small cell Lung Cancer (NSCLC) patients and evaluate targeted therapies (or combinations) in biomarker-driven sub-studies and immunotherapy combinations in patients previously exposed to standard checkpoint inhibitor therapy and lead to regulatory approval of efficacious regimens.

Accelerating Medicines Partnership: Rheumatoid Arthritis, Systemic Lupus Erythematosus & Related Autoimmune Disorders

Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus & Related Autoimmune Disorders is an initiative of the Accelerating Medicines Partnership (AMP), which is a multi-sector, pre-competitive  partnership among government, industry, and nonprofit organizations, the goal of which is to harness collective capabilities, scale and resources toward improving current efforts to develop new therapies for complex, heterogeneous diseases.

Support of Ebola Research by NIAID

In response to the critical Ebola Virus Disease (EVD) outbreak in 2014, the FNIH has established a fund that supports the Division of Clinical Research of the National Institute of Allergy and Infectious Diseases (NIAID) in its efforts to prevent, treat and research the EVD in West Africa.

Genome Research Fund

The Genome Research Fund supports genetics and genomics research at the National Human Genome Research Institute (NHGRI).

Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE)

The NIMBLE Project is a comprehensive, five-year collaborative effort to standardize, compare and appropriately validate imaging and circulating biomarkers for NASH to: 1. Diagnose and stage the disease and; 2. Measure response to therapeutic intervention.

Biomarkers Consortium - Workshop: Defining an Evidentiary Criteria Framework for Surrogate Endpoint Qualification

The FNIH Biomarkers Consortium and FDA hosted a workshop to provide a Framework for Defining the Evidentiary Criteria for Surrogate Endpoint Qualification on July 30-31, 2018. The workshop aimed to create alignment of the biomedical community and regulators on the levels of evidence required to qualify biomarkers for use in drug development, with an emphasis on surrogate endpoints and specific clinical outcome measures.

Biomarkers Consortium - Inflammatory Markers for Early Detection and Subtyping of Neurodegenerative and Mood Disorders

This project will aim to standardize and validate measurement methods for inflammatory markers associated with Alzheimer’s Disease and/or Major Depressive Disorder to ultimately identify a unique biosignature of disease. The identified biosignature would greatly assist with medication development, patient diagnosing, and patient selection for clinical trials.